The data support that KRAS pathway alterations are marked targets for therapy in a subset of patients with MPM, either as first-line therapy if they truly present tumor-initiating mutations, or as second-line therapy if they drive therapy-resistant KRAS-driven MPM subclones. The gene discussed is KRAS; the disease is neoplasm.